Ask AI

CNS-Active Systemic Therapy for HER2-Positive Breast Cancer

Explore CNS-active systemic therapy for HER2-positive breast cancer with brain metastases, including intracranial efficacy and safety evidence for antibody–drug conjugates and tucatinib-based regimens. Review how disease context and local therapy needs inform treatment selection and sequencing.

CNS Active Tx for HER2 Positive BC

Activity Information

Released: November 11, 2026